AI-guided drug formulation is enabling pharmaceutical developers to adjust modified-release compositions using data generated during clinical trials. Quotient Sciences tested a proprietary algorithm that entered its study trained on laboratory release data and was retrained after each dosing period using dissolution and pharmacokinetic results. The system then selected subsequent tablet compositions and doses, reaching a preset pharmacokinetic target within three dosing periods while operating within defined limits and human safety oversight.
The approach could reduce the repeated formulation development and clinical testing traditionally required to achieve specific drug-release profiles. For pharmaceutical and biotech companies, fewer development cycles could translate into shorter timelines, lower costs, and earlier decisions about promising drug candidates. Quotient Sciences can also strengthen its Translational Pharmaceutics platform by integrating AI-driven formulation selection with its existing development, manufacturing, and clinical testing services, creating a more streamlined offering for drug developers.
Image Credit: PeopleImages/Shutterstock
Why This Trend Is Growing
- Adaptive Clinical Formulation
- Real-time trial data is reshaping formulation design by allowing drug compositions and doses to evolve within controlled clinical study parameters.
- AI-driven Pharmacokinetics
- Predictive models tied to dissolution and pharmacokinetic results create new pathways for reaching target release profiles with fewer experimental cycles.
- Integrated Drug Development Platforms
- Combining formulation, manufacturing, clinical testing, and algorithmic decision-making supports more streamlined development services for pharmaceutical innovators.
Industries Being Reshaped
- Pharmaceuticals
- Drug makers gain opportunities to compress development timelines and reduce formulation risk through AI-supported clinical decision systems.
- Biotechnology
- Emerging biotech firms can benefit from faster evidence generation when formulation adjustments are informed by patient-stage data.
- Clinical Research Services
- Contract research and development providers are positioned to differentiate through integrated AI tools that connect trial execution with formulation optimization.
